Pyridostigmine Bromide Tablet
NDC 58657-810
Product Information
Pyridostigmine Bromide is a ANDA-approved product labeled by Method Pharmaceuticals, Llc. Pyridostigmine is used to improve muscle strength in patients with a certain muscle disease (myasthenia gravis). It is supplied as a white tablet for oral administration. This product entry covers the primary NDC 58657-810 and 3 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
IT;106
Code Structure Chart
Product Details
What is NDC 58657-810?
What are the uses of this product?
What are Active Ingredients of this product?
- PYRIDOSTIGMINE BROMIDE 30 mg/1 - A cholinesterase inhibitor with a slightly longer duration of action than NEOSTIGMINE. It is used in the treatment of myasthenia gravis and to reverse the actions of muscle relaxants.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- PYRIDOSTIGMINE BROMIDE (UNII: KVI301NA53)
- PYRIDOSTIGMINE (UNII: 19QM69HH21) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- SILICON DIOXIDE (UNII: ETJ7Z6XBU4)
- ANHYDROUS LACTOSE (UNII: 3SY5LH9PMK)
- STEARIC ACID (UNII: 4ELV7Z65AP)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 903841 - pyRIDostigmine bromide 30 MG Oral Tablet
- RxCUI: 903841 - pyridostigmine bromide 30 MG Oral Tablet
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.
Patient Education
Pyridostigmine
Pyridostigmine is used to decrease muscle weakness resulting from myasthenia gravis.
[Learn More]
* Please review the full disclaimer at the bottom of this page.